Supernus Pharmaceuticals (LTS:0LB2) Tariff Resilience Score: 8/10 (As of Jul. 03, 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $47.23
GF Value $40.00
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Tariff Resilience Score?

Supernus Pharmaceuticals LTS:0LB2 88 Tariff Resilience Score is 8 as of Jul. 03, 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.00 (Modestly Overvalued). Among 1,030 Drug Manufacturers companies, Supernus Pharmaceuticals ranks better than 99.61% on this metric.

Supernus Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Supernus Pharmaceuticals has Supernus Pharmaceuticals has low tariff exposure due to its focus on domestic pharmaceutical markets. The company relies on a domestic supply chain for production, reducing vulnerability to international trade tariffs. Historical impacts from tariffs have been negligible, with strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Supernus Pharmaceuticals might have Highly Resilient.

Supernus Pharmaceuticals  (LTS:0LB2) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Supernus Pharmaceuticals Tariff Resilience Score Related Terms

LTS:0LB2 vs BCRX, PBH, RGC: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Tariff Resilience Score falls into.


LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Tariff Resilience Score of 8 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Supernus Pharmaceuticals ranks #4 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Supernus Pharmaceuticals' Tariff Resilience Score too high?
Supernus Pharmaceuticals' current Tariff Resilience Score is 8. Based on the distribution chart, Supernus Pharmaceuticals ranks #4 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Tariff Resilience Score compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #4 out of 1030 companies for Tariff Resilience Score. This places Supernus Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Supernus Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.00, compared to a current price of $47.23 — trading 18.1% above its estimated fair value. The current Tariff Resilience Score is 8. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Tariff Resilience Score is 8 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.23 is trading 18.1% above its estimated GF Value™ of $40.00. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Tariff Resilience Score: 8
  • GF Value™: $40.00 vs. price of $47.23 (18.1% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.23
Price
$40.00
GF Value